CD274 and neoplasm: In a PD-1/PD-L1-resistant B16F10-R tumor mouse model, the combination of celecoxib and pembrolizumab (anti-PD-1 mAb) was shown to effectively reverse the drug resistance by increasing the number of immune cells infiltrating the TME [157].